Presentation is loading. Please wait.

Presentation is loading. Please wait.

All SAE* over time in 5 years.

Published byἌτλας Μεσσηνέζης Modified over 5 years ago

Similar presentations

Presentation on theme: "All SAE* over time in 5 years."— Presentation transcript:

1 All SAE* over time in 5 years.
All SAE* over time in 5 years. Each open circle represents a single SAE by MedDRA superclass term and time since first TCZ exposure. * SAE from patients randomly assigned to TCZ monotherapy in AMBITION who entered the LTE study. SAE: serious adverse event; MedDRA: Medical Dictionary for Regulatory Activities; TCZ: tocilizumab; AMBITION: Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy; LTE: longterm extension. Graeme Jones et al. J Rheumatol 2017;44: ©2017 by The Journal of Rheumatology

Download ppt "All SAE* over time in 5 years."

Similar presentations

Arthritis Advisory Committee July 29, 2008 Actemra (tocilizumab) for Rheumatoid Arthritis FDA Perspective Sarah Okada, M.D. Division of Anesthesia, Analgesia,

Arthritis Advisory Committee July 29, 2008 Actemra (tocilizumab) for Rheumatoid Arthritis FDA Perspective Sarah Okada, M.D. Division of Anesthesia, Analgesia,
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.
Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):545-554.

Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):
Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.

Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.
EudraVigilance.

EudraVigilance.
Alcohol, Other Drugs, and Health: Current Evidence

Alcohol, Other Drugs, and Health: Current Evidence
Valsartan in Acute Myocardial Infarction Trial Investigators

Valsartan in Acute Myocardial Infarction Trial Investigators
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018

Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Barrios C et al. SABCS 2009;Abstract 46.

Barrios C et al. SABCS 2009;Abstract 46.
Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,
EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Trial profile John A Dormandy et al. Lancet 2005;366:1279-89.

Trial profile John A Dormandy et al. Lancet 2005;366:
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Similar presentations

Ads by Google